keyword
MENU ▼
Read by QxMD icon Read
search

psoriasis cardiovascular event

keyword
https://www.readbyqxmd.com/read/28895664/the-severe-and-acute-complications-of-the-biologics-in-psoriasis
#1
Elias Oussedik, Nupur U Patel, Devin R Cash, Angela S Gupta, Steven R Feldman
Biologic therapies have revolutionized the approach to immune-mediated diseases such as psoriasis. Due to their favorable safety profiles and excellent efficacy, biologic agents are considered the gold-standard for moderate-to-severe psoriasis. The aim of this paper is to saliently review the severe and acute complications of the Food and Drug Administration (FDA) approved biologic agents for psoriasis. Reviewed agents include tumor necrosis factor alpha (TNF-alpha) inhibitors (etanercept, infliximab, and adalimumab), interleukin 12/23 inhibitors (ustekinumab), and interleukin 17 inhibitors (secukinumab and ixekizumab)...
September 12, 2017: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/28894050/compounds-of-psoriasis-with-obesity-and-overweight
#2
Agnieszka Owczarczyk-Saczonek, Waldemar Placek
Many epidemiological studies have confirmed the relationship of obesity and psoriasis, and it is believed that obesity is an independent risk factor for its development and is associated with a worse prognosis. Furthermore, the reduction of body weight, using low-calorie diet combined with exercise, reduces the severity of psoriasis.Visceral adipose tissue is the largest endocrine organ, producing proinflammatory cytokines (TNF-α, IL-6, IL-17) and adipokines (adiponectin, omentin, chemerin). They participate in the development of dyslipidemia, insulin resistance, diabetes, and consequently of the cardiovascular diseases...
August 24, 2017: Postȩpy Higieny i Medycyny Doświadczalnej
https://www.readbyqxmd.com/read/28855659/increased-risk-of-atrial-fibrillation-and-thromboembolism-in-patients-with-severe-psoriasis-a-nationwide-population-based-study
#3
Tae-Min Rhee, Ji Hyun Lee, Eue-Keun Choi, Kyung-Do Han, HyunJung Lee, Chan Soon Park, Doyeon Hwang, So-Ryoung Lee, Woo-Hyun Lim, Si-Hyuck Kang, Myung-Jin Cha, Youngjin Cho, Il-Young Oh, Seil Oh
Psoriasis increases the risk of atrial fibrillation (AF) and thromboembolic events (TE). There is limited information on the effect of psoriasis severity on AF and TE. In this study, psoriasis patients were enrolled from the Korean National Insurance Service-National Sample Cohort (2004-2008). Diagnosis and disease severity were determined from claims data. Newly diagnosed non-valvular AF and TE were identified during a 9.6-year follow-up. The effect of psoriasis severity on AF and TE was evaluated. We identified 13,385 psoriasis patients (1,947 with severe psoriasis)...
August 30, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28844116/cardiometabolic-disorders-in-psoriatic-disease
#4
REVIEW
Curtis Sobchak, Lihi Eder
PURPOSE OF REVIEW: Patients with psoriasis and psoriatic arthritis, collectively termed psoriatic disease (PsD), are at an increased risk of developing cardiovascular diseases (CVD). The purpose if this manuscript is to review recent evidence about the epidemiology and underlying mechanisms of CVD in psoriatic patients and approaches to improve the management of these comorbidities. RECENT FINDINGS: Studies have shown that CVD risk is independent of traditional cardiovascular risk factors and is related to the systemic inflammatory nature of PsD...
August 26, 2017: Current Rheumatology Reports
https://www.readbyqxmd.com/read/28837372/update-upon-efficacy-and-safety-of-etanercept-for-the-treatment-of-spondyloarthritis-and-juvenile-idiopathic-arthritis
#5
Giuseppe Murdaca, Simone Negrini, Ottavia Magnani, Elena Penza, Marco Pellecchio, Rossella Gulli, Paola Mandich, Francesco Puppo
TNF-α inhibitors have demonstrated efficacy both as monotherapy and in combination with disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of chronic inflammatory immune-mediated diseases such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis (AS), psoriasis (Ps) and/or psoriatic arthritis (PsA) and may be administered off-label to treat disseminated granuloma annulare, systemic lupus erythematosus and systemic sclerosis. There are several TNF-α inhibitors available for clinical use including infliximab, adalimumab, golimumab, certolizumab pegol and etanercept...
August 24, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28826925/the-relationship-between-duration-of-psoriasis-vascular-inflammation-and-cardiovascular-events
#6
Alexander Egeberg, Lone Skov, Aditya A Joshi, Lotus Mallbris, Gunnar H Gislason, Jashin J Wu, Justin Rodante, Joseph B Lerman, Mark A Ahlman, Joel M Gelfand, Nehal N Mehta
BACKGROUND: Psoriasis is associated with risk of cardiovascular (CV) disease (CVD) and a major adverse CV event (MACE). Whether psoriasis duration affects risk of vascular inflammation and MACEs has not been well characterized. OBJECTIVES: We utilized two resources to understand the effect of psoriasis duration on vascular disease and CV events: (1) a human imaging study and (2) a population-based study of CVD events. METHODS: First, patients with psoriasis (N = 190) underwent fludeoxyglucose F 18 positron emission tomography/computed tomography (duration effect reported as a β-coefficient)...
October 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28815476/long-term-safety-and-effectiveness-of-adalimumab-for-moderate-to-severe-psoriasis-results-from-7-year-interim-analysis-of-the-esprit-registry
#7
Alan Menter, Diamant Thaçi, Jashin J Wu, William Abramovits, Francisco Kerdel, Dilek Arikan, Dianlin Guo, Arijit Ganguli, Mareike Bereswill, Anne Camez, Wendell C Valdecantos
INTRODUCTION: ESPRIT (NCT00799877) is an ongoing 10-year international prospective observational registry evaluating the long-term safety and effectiveness of originator adalimumab in routine clinical practice for adult patients with chronic plaque psoriasis. Herein, we report the long-term safety, effectiveness, and patient-reported outcomes (PROs) following adalimumab treatment over the first 7 years of the ESPRIT registry. METHODS: All treatment-emergent (All-TE) adverse events (AE) since the initial (first ever) dose of adalimumab were assessed...
August 16, 2017: Dermatology and Therapy
https://www.readbyqxmd.com/read/28758265/risk-of-aortic-aneurysm-in-patients-with-psoriasis-a-retrospective-cohort-study
#8
LETTER
D J No, M Amin, L Duan, A Egeberg, O Ahlehoff, J J Wu
No abstract text is available yet for this article.
July 31, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28735613/does-treatment-of-psoriasis-reduce-cardiovascular-comorbidities
#9
REVIEW
Mark Lebwohl
Psoriasis has been associated with an increase in myocardial infarctions. Several registries have shown reductions in major adverse cardiovascular events in psoriasis patients and rheumatoid arthritis patients treated with tumor necrosis factor-α antagonists. Many assume that the reduction in cardiovascular events can be attributed to the anti-inflammatory effect of tumor necrosis factor blockers, but a 52-week study conducted by Bissonnette and coworkers failed to show a reduction in cardiovascular inflammation in psoriasis patients treated with adalimumab...
August 2017: Journal of Investigative Dermatology
https://www.readbyqxmd.com/read/28670544/randomized-placebo-control-study-of-metformin-in-psoriasis-patients-with-metabolic-syndrome-systemic-treatment-cohort
#10
Surjit Singh, Anil Bhansali
BACKGROUND: Psoriasis has been found to be associated with obesity, metabolic syndrome (MS), diabetes, and cardiovascular risk factors. Metformin treatment showed improvement in cardiovascular risk factors and hyperinsulinemia. OBJECTIVE: To evaluate the efficacy and safety of metformin in psoriasis patients with MS. MATERIALS AND METHODS: This was a single-center, parallel-group, randomized, open-label study with blinded end point assessment of metformin (1000 mg once daily for 12 weeks; n = 20) and placebo (n = 18) in psoriasis patients with MS...
July 2017: Indian Journal of Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28610662/clinical-diagnostic-and-therapeutic-implications-in-psoriasis-associated-with-cardiovascular-disease
#11
C Bonanad, E González-Parra, R Rivera, J M Carrascosa, E Daudén, A Olveira, R Botella-Estrada
In recent years the concept of psoriasis as a systemic disease has gained acceptance due to its association with numerous comorbid conditions, particularly atherosclerosis and cardiovascular disease. Several studies have shown that patients with psoriasis, especially younger patients and those with more severe forms of psoriasis or with psoriatic arthritis, have a higher prevalence of risk factors and metabolic syndrome, as well as an increased risk of major cardiovascular events such as myocardial infarction, cerebrovascular disease, and peripheral arterial disease...
June 10, 2017: Actas Dermo-sifiliográficas
https://www.readbyqxmd.com/read/28601812/cardiovascular-and-type-2-diabetes-morbidity-and-all-cause-mortality-among-diverse-chronic-inflammatory-disorders
#12
Alex Dregan, Phil Chowienczyk, Mariam Molokhia
OBJECTIVES: The present study aimed to assess the relationship between inflammatory disorders with cardiometabolic diseases and mortality within a community-based population. METHODS: The UK Biobank data were used to conduct two investigations: a cross-sectional study to estimate cardiometabolic risk and a prospective cohort study to estimate mortality risk. Binary regression analyses were used to model the association between coronary heart disease, stroke, type 2 diabetes, venous thromboembolism and peripheral artery disease diagnoses with seven inflammatory disorders (eg, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), psoriasis, ankylosing spondylitis (AS), systemic vasculitis, Crohn's disease and ulcerative colitis (UC))...
June 10, 2017: Heart: Official Journal of the British Cardiac Society
https://www.readbyqxmd.com/read/28573499/effectiveness-of-lipid-lowering-statin-therapy-in-patients-with-and-without-psoriasis
#13
William C Ports, Rana Fayyad, David A DeMicco, Rachel Laskey, Robert Wolk
BACKGROUND: Psoriasis is associated with dyslipidemia and metabolic syndrome, and has been linked to an increased cardiovascular risk. The aim of this study was to compare baseline characteristics and effects of statin therapy on lipid levels and cardiovascular outcomes in patients with and without psoriasis. METHODS: This post-hoc analysis assessed patients from one primary cardiovascular prevention statin trial (Collaborative AtoRvastatin Diabetes Study [CARDS]) and two secondary cardiovascular prevention statin trials (Treating to New Targets [TNT] and Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL])...
August 2017: Clinical Drug Investigation
https://www.readbyqxmd.com/read/28564678/association-between-skin-and-aortic-vascular-inflammation-in-patients-with-psoriasis-a-case-cohort-study-using-positron-emission-tomography-computed-tomography
#14
Amit K Dey, Aditya A Joshi, Abhishek Chaturvedi, Joseph B Lerman, Tsion M Aberra, Justin A Rodante, Heather L Teague, Charlotte L Harrington, Joshua P Rivers, Jonathan H Chung, Mohammad Tarek Kabbany, Balaji Natarajan, Joanna I Silverman, Qimin Ng, Gregory E Sanda, Alexander V Sorokin, Yvonne Baumer, Emily Gerson, Ronald B Prussick, Alison Ehrlich, Lawrence J Green, Benjamin N Lockshin, Mark A Ahlman, Martin P Playford, Joel M Gelfand, Nehal N Mehta
Importance: Inflammation is critical in the development of atherosclerosis. Psoriasis is a chronic inflammatory skin disease that is associated with increased vascular inflammation by 18fluorodeoxyglucose positron emission tomography/computed tomography in vivo and future cardiovascular events. It provides a human model to understand the effect of treating inflammation in a target organ (eg, the skin) on vascular diseases. Objective: To investigate the association between change in skin disease severity and change in vascular inflammation at 1 year and to characterize the impact of 1 year of anti-tumor necrosis factor therapy on vascular inflammation...
September 1, 2017: JAMA Cardiology
https://www.readbyqxmd.com/read/28441904/the-safety-of-ustekinumab-for-the-treatment-of-psoriatic-arthritis
#15
REVIEW
A López-Ferrer, A Laiz, L Puig
The cytokines interleukin (IL)-12 and IL-23 have been involved in the pathogenesis of psoriasis and psoriatic arthritis. Ustekinumab is a fully human monoclonal antibody targeting the p40 subunit shared by IL-12 and IL-23. Ustekinumab prevents the interaction of IL-12 and IL-23 binding to their receptors, blocking the T1 and T17 inflammatory pathways. Ustekinumab has been evaluated for the treatment of various chronic immune mediated diseases including psoriasis and psoriatic arthritis (PsA). Most of the data regarding the safety of ustekinumab come from the experience treating patients with psoriasis, but clinical trials have demonstrated its efficacy and safety in the treatment of both diseases...
June 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/28423301/risankizumab-versus-ustekinumab-for-moderate-to-severe-plaque-psoriasis
#16
RANDOMIZED CONTROLLED TRIAL
Kim A Papp, Andrew Blauvelt, Michael Bukhalo, Melinda Gooderham, James G Krueger, Jean-Philippe Lacour, Alan Menter, Sandra Philipp, Howard Sofen, Stephen Tyring, Beate R Berner, Sudha Visvanathan, Chandrasena Pamulapati, Nathan Bennett, Mary Flack, Paul Scholl, Steven J Padula
BACKGROUND: Interleukin-23 is thought to be critical to the pathogenesis of psoriasis. We compared risankizumab (BI 655066), a humanized IgG1 monoclonal antibody that inhibits interleukin-23 by specifically targeting the p19 subunit and thus prevents interleukin-23 signaling, and ustekinumab, an interleukin-12 and interleukin-23 inhibitor, in patients with moderate-to-severe plaque psoriasis. METHODS: We randomly assigned a total of 166 patients to receive subcutaneous injections of risankizumab (a single 18-mg dose at week 0 or 90-mg or 180-mg doses at weeks 0, 4, and 16) or ustekinumab (45 or 90 mg, according to body weight, at weeks 0, 4, and 16)...
April 20, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28384966/metabolic-syndrome-in-psoriasis-among-urban-south-indians-a-case-control-study-using-sam-ncep-criteria
#17
Banavasi S Girisha, Neetha Thomas
INTRODUCTION: Psoriasis is a chronic inflammatory disease of the skin associated with increased cardiovascular morbidity. Metabolic syndrome is a significant forecaster of cardiovascular events. AIM: To assess the association of metabolic syndrome and its components in patients with psoriasis and to compare it with the age and sex matched control group. MATERIALS AND METHODS: We conducted a hospital based case-control study on 156 adult patients with chronic plaque psoriasis and 156 patients with skin diseases other than psoriasis...
February 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28371532/prevalence-of-metabolic-syndrome-in-chinese-psoriasis-patients-a-hospital-based-cross-sectional-study
#18
Xin-Yu Gui, Xiao-Ling Yu, Hong-Zhong Jin, Ya-Gang Zuo, Chao Wu
AIMS/INTRODUCTION: Psoriasis, a chronic autoimmune skin disorder, is believed to contribute to cardiovascular diseases and metabolic syndrome. Psoriasis's association with the components of metabolic syndrome has been reported previously. However, large-scale cross-sectional studies about psoriasis and metabolic syndrome are rare in China. MATERIALS AND METHODS: We assessed the prevalence of metabolic syndrome in Chinese psoriasis patients and controls. RESULTS: A total of 859 psoriasis patients and 1,718 controls were recruited in an age- and sex-matched cross-sectional study...
March 30, 2017: Journal of Diabetes Investigation
https://www.readbyqxmd.com/read/28258057/psoriasis-as-a-human-model-of-disease-to-study-inflammatory-atherogenesis
#19
REVIEW
Charlotte L Harrington, Amit K Dey, Raza Yunus, Aditya A Joshi, Nehal N Mehta
Inflammation is known to play a significant role in the process of atherogenesis and cardiovascular disease (CVD). Indeed, patients with chronic inflammatory diseases are at increased risk for cardiovascular events. However, the mechanisms linking chronic inflammation and CVD remain poorly understood. Psoriasis, a chronic inflammatory skin disease associated with a greater risk of early cardiovascular events, provides a suitable human model to study the pathophysiology of inflammatory atherogenesis in humans...
May 1, 2017: American Journal of Physiology. Heart and Circulatory Physiology
https://www.readbyqxmd.com/read/28213804/psoriasis-and-cardiovascular-events-updating-the-evidence
#20
Line Raaby, Ole Ahlehoff, Annette de Thurah
So far, systematic reviews have suggested an increased risk of cardiovascular diseases (CVD) in psoriatic patients, though some results have been conflicting. The aim of this study was to update the current level of evidence through a systematic search in MEDLINE, EMBASE and Cochrane Central Register databases. In total, 13 high-quality observational studies estimating the incidence of CVD were included. Patients with mild psoriasis had an increased risk of stroke [Hazard ratio (HR) = 1.10, 95% CI: 1.0-1...
April 2017: Archives of Dermatological Research
keyword
keyword
114302
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"